Mirati Therapeutics, Inc. (MRTX)
| Market Cap | 8.08B |
| Revenue (ttm) | 13.13M |
| Net Income (ttm) | -406.96M |
| Shares Out | 50.78M |
| EPS (ttm) | -8.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $157.13 |
| Previous Close | $159.33 |
| Change ($) | -2.20 |
| Change (%) | -1.38% |
| Day's Open | 159.60 |
| Day's Range | 153.83 - 159.77 |
| Day's Volume | 272,985 |
| 52-Week Range | 115.44 - 249.42 |
Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.
The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc's (NASDAQ: MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients with the KRAS-G12C mutation. The decision was ba...
SAN DIEGO, June 24, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced today that the U.S. Food and Drug Administration (FDA) has grante...
SAN DIEGO, June 2, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Goldman Sachs Global He...
SAN DIEGO and SHANGHAI and SAN FRANCISCO, June 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688...
QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.
SAN DIEGO, May 6, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter of 2021 and recent cor...
Mirati Therapeutics (MRTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
SAN DIEGO, April 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced initial preclinical results evaluating its investigational syn...
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
SAN DIEGO, March 31, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced its Board of Directors has elected a new independent director,...
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covi...
SAN DIEGO, March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's synt...
SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, ...
SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences. Friday, February 26th ...
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a fireside chat at the Guggenheim H...
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San Fra...
Leveraging sound science and prudent cancer treatment, Mirati is growing robustly. The two lead drugs (sitravatinib and Adagrasib) are rapidly advancing for different cancer indications.
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Everco...
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual ...
SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in r...
SAN DIEGO, Oct. 30, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common s...
Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the...
Promising results from a study of its cancer drug pushed Mirati Therapeutics Inc. (NASDAQ:MRTX) to an all-time high Monday. Shares of the San Diego-based biotech hit more than $210 and are at about $205...
Which one of these biotech stocks has a better chance to provide market-beating gains?
SAN DIEGO, Oct. 26, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares of its com...
Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The biotech's positive clinical results announced on Sunday prompted analysts to boost their price targets on the stock.
Tiny Mirati Therapeutics posted positive preliminary data on a colorectal and lung cancer drug therapy in competition with drug giant Amgen, sending MRTX stock soaring to an all-time high. The post Tiny...
SAN DIEGO, Oct. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced preliminary results from the Company's mutant KRAS selectiv...
Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Mir...
SAN DIEGO, Oct. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical data from adagrasib (MRTX849), the Company...
LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.
Mirati achieves positive results in phase 2 open-label study using sitravatinib to treat patients with metastatic or advanced urothelial carcinoma who have the KRAS mutation.
LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.
SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating...
INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a S...
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 13, 2020 /PRNewswire/ -- Strata Oncology, Inc.
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.
ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor
Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About MRTX
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in precli... [Read more...]
| Industry Biotechnology | IPO Date Jun 29, 2004 |
| CEO Charles Baum | Employees 199 |
| Stock Exchange NASDAQ | Ticker Symbol MRTX |
Financial Performance
In 2020, MRTX's revenue was $13.40 million, an increase of 301.74% compared to the previous year's $3.34 million. Losses were -$357.94 million, 67.8% more than in 2019.
Analyst Forecasts
According to 15 analysts, the average rating for MRTX stock is "Buy." The 12-month stock price forecast is 227.78, which is an increase of 44.96% from the latest price.